Cheryl L. Maier

Cheryl L. Maier

Auto-generated profile, based on publicly available information

Cheryl L. Maier

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in The Lancet
Verified
Journal Article
Closed access
CMCheryl L Maier
Cheryl L Maier
ATAlexander D Truong
Alexander D Truong
SASara C Auld
Sara C Auld
DPDerek M Polly
Derek M Polly
CTChristin-Lauren Tanksley
Christin-Lauren Tanksley
ADAlexander Duncan
Alexander Duncan

31 August 2022 in Nature
Verified
Journal Article
Open access
PDF file
MWMatthew C. Woodruff
Matthew C. Woodruff
RRRichard P. Ramonell
Richard P. Ramonell
NHNatalie S. Haddad
Natalie S. Haddad
FAFabliha A. Anam
Fabliha A. Anam
MRMark E. Rudolph
Mark E. Rudolph
ISIgnacio Sanz
Ignacio Sanz
Severe SARS-CoV-2 infection1 has been associated with highly inflammatory immune activation since the earliest days of the COVID-19 pandemic2–5. More recently, these responses have been associated with the emergence of self-reactive antibodies with pathologic potential6–10, although their origins and resolution have remained unclear11. Previously, we and others have identified extrafollicular B cell activation, a pathway associated with the formation of new autoreactive antibodies in chronic autoimmunity12,13, as a dominant feature of severe and critical COVID-19 (refs. 14–18). Here, using single-cell B cell repertoire analysis of patients with mild and severe disease, we identify the expansion of a naive-derived, low-mutation IgG1 population of antibody-secreting cells (ASCs) reflecting features of low selective pressure. These features correlate with progressive, broad, clinically relevant autoreactivity, particularly directed against nuclear antigens and carbamylated proteins, emerging 10–15 days after the onset of symptoms. Detailed analysis of the low-selection compartment shows a high frequency of clonotypes specific for both SARS-CoV-2 and autoantigens, including pathogenic autoantibodies against the glomerular basement membrane. We further identify the contraction of this pathway on recovery, re-establishment of tolerance standards and concomitant loss of acute-derived ASCs irrespective of antigen specificity. However, serological autoreactivity persists in a subset of patients with postacute sequelae, raising important questions as to the contribution of emerging autoreactivity to continuing symptomology on recovery. In summary, this study demonstrates the origins, breadth and resolution of autoreactivity in severe COVID-19, with implications for early intervention and the treatment of patients with post-COVID sequelae.

9 April 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
Toshiaki IbaToshiaki Iba
Toshiaki Iba
Jerrold H LevyJerrold H Levy
Jerrold H Levy
CMCheryl L. Maier
Cheryl L. Maier
JBJulie Boisrame-Helms
Julie Boisrame-Helms
YUYutaka Umemura
Yutaka Umemura
ESEcaterina Scarlatescu
Ecaterina Scarlatescu

24 April 2024 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
Toshiaki IbaToshiaki Iba
Toshiaki Iba
CMCheryl L. Maier
Cheryl L. Maier
JBJulie Boisrame-Helms
Julie Boisrame-Helms
RFRicard Ferrer
Ricard Ferrer
JTJecko Thachil
Jecko Thachil
Jerrold H LevyJerrold H Levy
Jerrold H Levy
Maintaining tissue perfusion in sepsis depends on vascular integrity provided by the endothelial glycocalyx, the critical layer covering the luminal surface of blood vessels. The glycocalyx is composed of proteoglycans, glycosaminoglycans, and functional plasma proteins that are critical for antithrombogenicity, regulating tone, controlling permeability, and reducing endothelial interactions with leukocytes and platelets. Degradation of the glycocalyx in sepsis is substantial due to thromboinflammation, and treatments for sepsis and septic shock may exacerbate endotheliopathy via additional glycocalyx injury. As a result, therapeutic strategies aimed at preserving glycocalyx integrity should be considered, including modifications in fluid volume resuscitation, minimizing catecholamine use, controlling hyperglycemia, and potential use of corticosteroids and anticoagulants. In this review, we explore treatment strategies aligned with the recommendations outlined in the Surviving Sepsis Campaign Guidelines 2021 with a special emphasis on evidence regarding glycocalyx protection.

16 October 2012 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SSSean R. Stowell
Sean R. Stowell
AWAnne M. Winkler
Anne M. Winkler
CMCheryl L. Maier
Cheryl L. Maier
CAC. Maridith Arthur
C. Maridith Arthur
NSNicole H. Smith
Nicole H. Smith
JHJeanne Hendrickson
Jeanne Hendrickson
Hemolytic transfusion reactions represent one of the most common causes of transfusion-related mortality. Although many factors influence hemolytic transfusion reactions, complement activation represents one of the most common features associated with fatality. In this paper we will focus on the role of complement in initiating and regulating hemolytic transfusion reactions and will discuss potential strategies aimed at mitigating or favorably modulating complement during incompatible red blood cell transfusions.

19 February 2024 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
Toshiaki IbaToshiaki Iba
Toshiaki Iba
JBJulie Boisrame-Helms
Julie Boisrame-Helms
CMCheryl L. Maier
Cheryl L. Maier
MLMarcel Levi
Marcel Levi
ESEcaterina Scarlatescu
Ecaterina Scarlatescu
Jerrold H LevyJerrold H Levy
Jerrold H Levy